Josh Schafer - Research Ecosystem

Watch John Schafer's Video Response Collaboration amongst various entities across the research and development continuum are becoming more varied within the field of oncology. It is common for pharmaceutical companies to collaborate on clinical trials that test the effects of various drug combinations, or to partner to share commercial sales and marketing efforts.  We are now also seeing these same companies partner with government agencies like the Food and Drug Administration (FDA) and National Institutes of Health (NIH). One such example is The Biomarkers Consortium, a research partnership managed by the Foundation for the National Institutes of Health. This public-private biomedical research alliance is working on advancing drug development by discovering and qualifying biomarkers. Additionally, patient advocacy groups such as Multiple Myeloma Research Foundation or the Leukemia and Lymphoma Society are partnering with pharmaceutical companies to fund and conduct clinical trials. And, many of the most recent advances in cancer research have come from collaborations between companies and academic research institutions. Open source clinical data is one of the most exciting and promising results of collaboration. In this effort, companies are pooling their collective clinical trial data and making it available to others. Sharing data will hopefully lead to a more streamlined clinical trial process, which will lead to faster and better drug development. Collaborations are ve...
Source: PHRMA - Category: Pharmaceuticals Authors: Source Type: news